Cantitate/Preț
Produs

Pulmonary Involvement in Patients with Hematological Malignancies

Editat de Elie Azoulay
Notă GoodReads:
en Limba Engleză Carte Hardback – 02 May 2011

The number of patients treated for hematological malignancies is increasing steadily. To maximize cure rates, aggressive treatments have been introduced, including high-dose chemotherapy, stem cell transplantation, and targeted therapies. As a result, overall and disease-free survival rates have improved substantially, but at the price of life-threatening toxic and infectious complications that chiefly target the lung. This book provides clinicians caring for patients with hematological malignancies with detailed, up-to-date information on all relevant aspects of pulmonary involvement. Individual sections are devoted to epidemiology, diagnostic strategy, lung infections, non-infectious pulmonary involvement, and treatment, including decision making in patients with acute respiratory failure. Each of these sections contains a number of chapters, all written by leading international experts. In addition, the reader’s attention is drawn to important "pearls" relating to each condition.

Citește tot Restrânge
Toate formatele și edițiile
Toate formatele și edițiile Preț Express
Carte Paperback (1) 109603 lei  Economic 36-50 zile
  Springer – 23 Aug 2016 109603 lei  Economic 36-50 zile
Carte Hardback (1) 108439 lei  Economic 36-50 zile +39288 lei  10-17 zile
  Springer – 02 May 2011 108439 lei  Economic 36-50 zile +39288 lei  10-17 zile

Preț: 108439 lei

Preț vechi: 114147 lei
-5%

Puncte Express: 1627

Preț estimativ în valută:
22182 26134$ 19814£

Carte tipărită la comandă

Livrare economică 29 octombrie-12 noiembrie
Livrare express 03-10 octombrie pentru 40287 lei

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783642157417
ISBN-10: 3642157416
Pagini: 846
Ilustrații: 98 schwarz-weiße und 63 farbige Abbildungen
Dimensiuni: 193 x 260 x 43 mm
Greutate: 1.96 kg
Ediția: 2011
Editura: Springer
Colecția Springer
Locul publicării: Berlin, Heidelberg, Germany

Public țintă

Professional/practitioner

Cuprins

Preamble and Introduction.-Epidemiology.- Diagnostic Strategy in Hematologic Malignancies Patients.- Lung Infections in Patients with Hematologic Malignancies.-Noninfectious Pulmonary Involvement in Patients with Hematologic Malignancies.- Treatment and Difficult Decisions in Patients with Hematologic Malignancies.-Pearls that You Should be Aware of.-Post Face.


Recenzii

From the reviews:
“This is a detailed, multiauthored review of infectious, inflammatory, and thromboembolic complications in patients with a variety of hematological cancers. … Practitioners with an interest in hematological malignancy and intensivists providing critical care resources for management of these patients are an appropriate audience for this work coming from an international panel of authors, the majority of whom are from France. … This unique book effectively reviews the current therapy, incidence, and outcomes for this complex patient group.” (David J. Dries, Doody’s Review Service, December, 2011)

Notă biografică

Dr Élie Azoulay is the Assistant Director of the Medical ICU at the Saint-Louis Teaching Hospital, Paris, France. He is a professor of medicine at the Denis Diderot Paris 7 University. From his background as a pulmonologist, Dr Azoulay developed a strong research focus on acute respiratory failure in immunocompromized patients. His PhD work was on respiratory physiology in an experimental model of cancer chemotherapy-related pulmonary toxicity. He has several published clinical research studies on acute respiratory failure in hematology and oncology patients. Also, Dr Azoulay leads a collaborative multicenter group that has performed observational studies, large cohort studies, and randomized controlled trials in cancer patients with ARF. His second major field of interest in clinical research is communication with family members of ICU patients. He constituted a research group in 1997 (the French Famirea Study Group) to evaluate the ability of critical care clinicians to provide effective information to ICU patients and families. Several of his published studies investigated the burden of critical illness in relatives and in ICU clinicians. The group’s major aim is to identify targets for improvement and to test potential interventions in international RCTs in order to advance ICU practices in the field of information and communication. In addition to clinical and research activities, Dr Azoulay teaches pulmonary medicine, critical care medicine, and ethics at the Paris Medical School. He is also associate editor of Intensive Care Medicine, in the editorial board of the American Journal of respiratory and Critical Care medicine, and the chairman of the ethics section of the ESICM. Dr Azoulay is a member of the European board of Pfizer and Gilead.


Textul de pe ultima copertă

The number of patients treated for hematological malignancies is increasing steadily. To obtain the highest possible cure rates, aggressive treatments have been introduced, including high-dose chemotherapy, stem cell transplantation, and targeted therapies. As a result, overall and disease-free survival rates have improved substantially; however, this has been achieved at the price of life-threatening toxic and infectious complications that chiefly target the lung. This book provides clinicians caring for patients with hematological malignancies with detailed, up-to-date information on all relevant aspects of pulmonary involvement. Individual sections are devoted to epidemiology, diagnostic strategy, lung infections, non-infectious pulmonary involvement, and treatment, including decision making in patients with acute respiratory failure. Each of these sections contains a number of chapters, all written by leading international experts. In addition, the reader’s attention is drawn to important "pearls" relating to each condition.


Caracteristici

Detailed, up-to-date information is provided on all relevant aspects of pulmonary involvement in patients with hematological malignancies
Leading experts discuss epidemiology, diagnostic strategy, lung infections, non-infectious pulmonary involvement, and treatment, including decision making in patients with acute respiratory failure
Invaluable "pearls" relating to each condition are presented